Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gardasil Efficacy in Young Men
NCT00090285Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2004
- Primary completion
- Jul 2009
- Modality
- Vaccines & Immunotherapeutics
01
Overview
A Phase 3 trial of recombinant human papillomavirus 9-valent vaccine in condylomata acuminata, anal intraepithelial neoplasia (AIN), anal cancer, human papillomavirus infection, penile intraepithelial neoplasia (PeIN), sponsored by Merck & Co.. Started Sep 2004; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
condylomata acuminataanal intraepithelial neoplasia (AIN)anal cancerhuman papillomavirus infectionpenile intraepithelial neoplasia (PeIN)
Beyond the preview
Go deeper on NCT00090285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00090285.